Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

June 30, 2011

Study Completion Date

October 31, 2011

Conditions
HIV Lipodystrophy
Interventions
DRUG

"Human recombinant leptin (metreleptin)"

Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.

DRUG

Placebo

Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT01511016 - Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome | Biotech Hunter | Biotech Hunter